The long-planned 'modernization' of the US FDA's Office of New Drugs is expected to nearly double OND's organizational chart. OND, housed within the Center for Drug Evaluation and Research, would add four offices overseeing review operations (for a total of nine) and 11 drug review divisions (for a total of 30).
The proposed structural changes – which are still somewhat in flux and are subject to further internal administrative review and...








